Building and optimising portfolios thought leadership

Return to all the latest news and thought leadership

Asset Evaluation

2019-11-08T11:21:43+00:00October 28th, 2019|Case Study|

Our client was a medium-sized pharma company interested in launching an antibiotic asset for treating pathogens with limited treatment options in Central and Southern Europe, as well as the Middle East. Their antibiotic was a particularly strong candidate for commercialization due to its novelty in tackling multi-resistant antibiotic pathogens and the extremely high unmet demands in the targeted regions. Our client engaged us to work with their business intelligence managers in order to evaluate the commercial value of the asset and to advise on the best strategic route to commercialization.

Purchasing a Pipeline

2019-11-08T14:30:03+00:00April 23rd, 2019|White Paper|

Perils, pitfalls, and priorities in asset acquisition. In this White Paper, we will look at new and changing trends in pipeline acquisition, discuss difficulties inherent in the current marketplace, and offer worthwhile perspectives on pitfalls and opportunities based on our experience offering strategic guidance to pharmaceutical companies on a global scale.